AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04861285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RACEGEL without cord
Description: The dentist applies a sufficient amount of RACEGEL directly into the sulcus, following the contour of the prepared tooth. The gel is left in place a few minutes and then removed. The sulcus is washed and gently air-dried before taking impression.
Study NCT02312596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRP Concepts Fibrin Bio-Matrix
Description: Application of PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
Study NCT02312596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual and Customary Practice
Description: Usual and customary care for non-healing wounds
Study NCT02312596 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual and Customary Practice
Description: Usual and customary care for non-healing wounds
Study NCT04971148 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HFNC flow set at patient peak tidal inspiratory flow
Description: HFNC flow will be set at the level equal to patient peak tidal inspiratory flow
Study NCT04971148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFNC flow set at 1.33 times of patient peak tidal inspiratory flow
Description: HFNC flow will be set at 1.33 times of patient peak tidal inspiratory flow
Study NCT04971148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFNC flow set at 1.67 times of patient peak tidal inspiratory flow
Description: HFNC flow will be set at 1.67 times of patient peak tidal inspiratory flow
Study NCT04971148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFNC flow set at 2 times of patient peak tidal inspiratory flow
Description: HFNC flow will be set 2 times of patient peak tidal inspiratory flow
Study NCT05182359 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) Test and SomaSignal Metabolic Factors test
Description: The SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) test is used to predict the four-year likelihood of myocardial infarction, stroke, hospitalization for heart failure or death. It will be provided to the participant's ordering provider.
Study NCT03326128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion Hydrochloride
Description: Antidepressant that is also effective in smoking cessation
Study NCT03326128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Hydrochloride
Description: Antidepressant that is also effective in smoking cessation
Study NCT04801966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: 2 mg per day, continuous
Study NCT04801966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: 60 mg/day for 21 days of a 28 day cycle
Study NCT04801966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: 45 mg/twice a day, continuous
Study NCT04801966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: 300 mg/day, continuous
Study NCT04801966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 960 mg/twice per day, continuous
Study NCT04801966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: 150 mg/twicce per day, continuous
Study NCT04801966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: 450 mg/day, continuous
Study NCT04801966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 125 mg/day, day 1-21 of a 28 day cycle
Study NCT04801966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg/twice per day, continuous
Study NCT04801966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: 600 mg/day, on day 1 -21 of a 28 day cycle
Study NCT04801966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 150 mg twice/day, continuous
Study NCT04801966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: 1 mg/day, on day 1 -28 of each 28 day cycle
Study NCT04801966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg IV once every 2 weeks
Study NCT04801966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg IV on Day 1 of a 21 day cycle
Study NCT04801966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV on day 1 of a 21 day cycle
Study NCT04832230 — intervention group
Intervention type: OTHER
Intervention: Hearing test
Description: The hearing test is composed of several examinations:~* pure tone audiogram~* otoscopy~* tympanometry~Healthy individuals: The hearing test will be performed at enrollment (Day 0). Patients: The hearing test will be performed at Day 1, Day 3, Day 7 and Day 30.
Study NCT04832230 — intervention group
Intervention type: OTHER
Intervention: Questionnaire about previous noise exposure
Description: The participant will have to fill in a questionnaire about his/her previous noise exposure at enrollment (Day 0).
Study NCT04832230 — intervention group
Intervention type: OTHER
Intervention: Otoacoustic emission measurement
Description: Healthy individuals: Otoacoustic emission will be measured at enrollment (Day 0).~Patients: Otoacoustic emission will be measured at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30.
Study NCT04832230 — intervention group
Intervention type: OTHER
Intervention: Electrocochleography
Description: Healthy individuals: Electrocochleography will be performed at enrollment (Day 0).~Patients: Electrocochleography will be performed at Day 30.
Study NCT04832230 — intervention group
Intervention type: OTHER
Intervention: Speech audiometry in noise
Description: Healthy individuals: Speech audiometry in noise will performed at enrollment (Day 0).~Patients: Speech audiometry in noise will performed at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30.
Study NCT04832230 — intervention group
Intervention type: OTHER
Intervention: Multi-frequency impedance measurement
Description: Healthy individuals: Multi-frequency impedance will be measured at enrollment (Day 0).~Patients: Multi-frequency impedance will be measured at Day 30.
Study NCT04832230 — intervention group
Intervention type: OTHER
Intervention: Assessment of tinnitus severity
Description: Tinnitus severity will be assessed using a visual analogic scale at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30.
Study NCT04832230 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample collection
Description: Healthy individuals: A blood sample will be collected at enrollment (Day 0). Patients: A blood sample will be collected at enrollment (Day 0), at Day 1, Day 3, Day 7 and Day 30.
Study NCT04480203 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stressproffen cognitive based stress management
Description: The participants will download an app (Stressproffen 2A) with cognitive based stress management.
Study NCT04480203 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stressproffen mindfulness based intervention
Description: The participants will download an app (Stressproffen 2B) with mindfulness based intervention.
Study NCT04480203 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The participants will receive no app. (They will be able to download it after the end of the 3 year study).
Study NCT06054932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LK101 injection
Description: LK101 administrated Q2W as the prime dose, and Q3W in the boost phase
Study NCT06054932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LK101 injection
Description: LK101 administrated QW as the prime dose, and Q3W in the boost phase
Study NCT05096325 — intervention group
Intervention type: DEVICE
Intervention: YpsoPump® insulin pump system
Description: The subjects will receive a CE-certified mylife™ YpsoPump® insulin pump system that allows detailed logging of pressure data. Data will then be analysed in silico comparing the new occlusion detection algorithm with the common occlusion detection algorithm.
Study NCT03933657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SoundBite™ Crossing System - Peripheral
Description: SoundBite™ Crossing System consisting of the SoundBite™ Console and SoundBite™ Active Wire 18. The Investigator may use the SoundBite™ Active Wire during the procedure to cross the proximal aspect and/or to cross multiple lesions.
Study NCT05104216 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine
Description: receive a third dose of inactivated COVID-19 vaccine
Study NCT06263998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCP112
Description: NCP112 topical ophthalmic solution
Study NCT06263998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NCP112 Placebo
Description: Placebo comparator
Study NCT06545773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root Canal Treatment with ProTaper Next Nickel-Titanium File (PTN)
Description: ProTaper Next (Dentsply Sirona) is a rotational system made of a nickel-titanium alloy called M-Wire. It has a rectangular cross-sectional design; thus, only two sides touch the root canal. Five files are available: X1 17/. 04, X2 25/.06, X3 30/. 07, X4 40/.06, and X5 50/.06. This file aggressively removes the coronal dentine of root canals due to its large taper. PTN nickel-titanium systemis used in root canal treatments to debride and shape the root canals.
Study NCT06545773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root Canal Treatment withTruNatomy Nickel-Titanium File (TN)
Description: TruNatomy (Dentsply Sirona) is a heat-treated nickel-titanium system that consists of an orifice modifier, glide path, and shaping files. The TruNatomy Small, Prime, and Medium files have sizes of 20/.04, 26/.04, and 35/.04, respectively. It has a rectangular cross-section and a regressive taper. Its slim design allows for a conservative preparation of root canals and the preservation of the coronal dentine. TN nickel-titanium system is used in root canal treatments to debride and shape the root canals.
Study NCT06305741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Managing Anxiety from Cancer (MAC)
Description: The intervention, MAC, is a seven-session (45-60 minutes per session) psychotherapy intervention delivered via videoconference.~and/or telephone by licensed social workers
Study NCT05988463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate Oral Product
Description: Artesunate capsules administered orally twice daily beginning at 10 mg for 4 weeks, followed by 20 mg for 4 weeks, and then 30 mg for 4 weeks.
Study NCT06149650 — intervention group
Intervention type: DEVICE
Intervention: Shockwave Medical IVL System
Description: Comprehensive system consisting of generator, a connector cable and a single-use sterile catheter with integrated balloon for intravascular lithotripsy of peripheral artery calcification.
Study NCT05024097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant (AB928)
Description: Patients will receive a radiation therapy dose of 25Gy in 5 fractions in combination with etrumadenant 150 mg orally, once daily as part of a continuous dose regimen.
Study NCT05024097 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Patients will receive a radiation therapy dose of 25Gy in 5fx
Study NCT05024097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: After completing the radiation therapy, patients will receive FOLFOX regimen for 9 cycles in combination with etrumadenant and zimberelimab. All patients will be offered adjuvant zimberelimab for up to one year.
Study NCT05024097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab (AB122)
Description: After completing the radiation therapy, patients will receive FOLFOX regimen for 9 cycles in combination with etrumadenant and zimberelimab. All patients will be offered adjuvant zimberelimab for up to one year.
Study NCT06015503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLB1004
Description: PLB1004 is a capsule in the form of 80mg and 40mg.
Study NCT06532864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice Mawangdui Guiding Technique
Description: Nursing staff with experience in teaching Mawangdui Daoyin Exercise conducted the operation instruction on different floors. A feasibility assessment of the older adults was carried out by the nursing staff at the end of the teaching, and only after passing this assessment could the experimental part begin. The treatment group participated in five Mawangdui Daoyin Exercise sessions per week, each lasting approximately 45 minutes, and the exercises continued for 12 weeks.
Study NCT05581303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given by subcutaneous injection once every 12 weeks (Q12W).
Study NCT05581303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olpasiran
Description: Olpasiran given by subcutaneous injection Q12W.
Study NCT04315233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib Dose Level 0 (starting dose) 200mg QD Dose Level 1A 400mg QD on Days 8-28 Dose Level 1B 200mg QD Dose Level 2 400mg QD on Days 8-28
Study NCT04315233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Belinostat Dose Level 0 (starting dose) 600mg/m2 daily for 5 days Dose Level 1A 600mg/m2 daily for 5 days Dose Level 1B 1000mg/m2 daily for 5 days Dose Level 2 1000mg/m2 daily for 5 days~\*Administration on 5 consecutive days is preferred. Administration within 7 days allowed as needed to accommodate holidays and infusion schedules.
Study NCT06353126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DEB-TACE
Description: DEB-TACE, or Drug-Eluting Bead Transarterial Chemoembolization, is a minimally invasive interventional radiology procedure primarily used in the treatment of hepatocellular carcinoma (HCC), which is the most common type of liver cancer. This procedure combines two treatment modalities: transarterial chemoembolization (TACE) and the use of drug-eluting beads (DEB).~During DEB-TACE, tiny beads loaded with chemotherapy drugs are injected directly into the blood vessels supplying the tumor in the liver. These drug-eluting beads gradually release chemotherapy agents, delivering a targeted and sustained dose directly to the cancerous tissue while minimizing systemic side effects. Additionally, the beads themselves act as embolic agents, blocking the blood flow to the tumor and causing ischemia, which further contributes to the destruction of the tumor cells.
Study NCT06347055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Continuous theta burst rTMS
Study NCT05051254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Esogastric pressure measurement
Description: Measurement of work of breathing and respiratory muscles strength using an esogastric catheter.~One measurement or before and after (6 months and 1 year) the initiation of a pharmacological treatment in order to assess the effect of the treatment on respiratory muscle function.
Study NCT06562153 — intervention group
Intervention type: OTHER
Intervention: Neuroimaging with Magnetic Resonance Imaging (MRI)
Description: MRI will be used to observe brain states over time.
Study NCT05365646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aids equipped with motion sensing abilities
Description: Participants will wear hearing aids that will assess their movement, and fall risk.
Study NCT05681468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Keto-SAT
Description: Nutrition counselling focused on Keto diet (saturated fat).~10% TE as carbohydrate (mainly from vegetables and whole grain products), protein between 20-30% TE and fat between 60-70%.
Study NCT05681468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Keto-CAN
Description: Nutrition counselling focused on Keto diet (unsaturated fat).~10% TE as carbohydrate (mainly from vegetables and whole grain products), protein between 20-30% TE and fat between 60-70%.
Study NCT05681468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LFD
Description: Nutrition counselling focused on low-fat diet.~30% total energy (TE) as fat, 50% TE as carbohydrates (primarily whole grains) and 17-20% TE protein (mainly lean sources).
Study NCT05219292 — intervention group
Intervention type: OTHER
Intervention: Active music therapy
Description: Active music therapy is not a musical learning process. The restrictive character of classical respiratory rehabilitation will be alleviated by the playful aspect and the pleasure generated by the sessions, which will facilitate the commitment of the patients in their post-transplant respiratory rehabilitation.~The recorder was chosen among other wind instruments for several reasons:~* Its use is simple,~* It acts as an oscillating exhalation resistance device that generates a positive expiratory pressure (auto-PEP) produced by this wind instrument allows to obtain conditions similar to the treatment performed by a flutter (classical respiratory rehabilitation), a pressure on the expiratory flow with the obtaining of an oscillating effect during the trills, an increase of the respiratory capacities,~* The characteristics of the sound it produces (duration, intensity, timbre and frequency) will generate auditory feedback allowing patients to become aware of their breathing patterns.
Study NCT05219292 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: We chose the HAD (Hospital Anxiety and Depression Scale) to assess anxiety and depression. This test is a reference test, often used in studies of transplant patients. The results obtained in previous studies allowed us to create our hypotheses.~To measure pain we chose the visual analogue scale (VAS). This reference test is often used in pain studies. It has the advantage of being simple to perform and easy to understand.~Quality of life will be assessed using the SF-12 (Short Form 12 Health Survey Questionary). We consider it to be simple and easy for patients to understand.
Study NCT06400459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVW-1001 Ophthalmic Eyelid Wipe 0.1%
Description: IVW-1001 Ophthalmic Eyelid Wipe 0.1%
Study NCT06400459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVW-1001 Ophthalmic Eyelid Wipe 0.2%
Description: IVW-1001 Ophthalmic Eyelid Wipe 0.2%
Study NCT06400459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IVW-1001 Placebo
Description: IVW-1001 Placebo
Study NCT06051123 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Participants will be taking 1 sachet a day.
Study NCT06051123 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be taking 1 sachet a day.
Study NCT05218356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Covidir injections
Description: administration of the investigational product CODIVIR/Placebo at a dose of 20 mg twice a day subcutaneously at visits Day0-Day6 (7 days total)
Study NCT05218356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Covidir injections
Description: administration of the investigational product CODIVIR/Placebo at a dose of 20 mg twice a day subcutaneously at visits Day0-Day6 (7 days total)
Study NCT05218356 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantitative PCR SARS-CoV-2
Description: detection of viral RNA in nasopharyngeal and oropharyngeal samples by the Real Time Protein Chain Reaction technique.
Study NCT05218356 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Quantitative PCR SARS-CoV-2
Description: detection of viral RNA in nasopharyngeal and oropharyngeal samples by the Real Time Protein Chain Reaction technique.
Study NCT05218356 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IgM and IgG dosage
Description: lood collection for dosage of Anti SARS-CoV-2 antibodies.
Study NCT05218356 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: IgM and IgG dosage
Description: lood collection for dosage of Anti SARS-CoV-2 antibodies.
Study NCT05218356 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Screening Blood tests
Description: omplete blood count, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubins and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides); coagulogram (TP, aPTT); D-dimer; C-reactive protein; HIV, HBV, HCV serology; Ferritin; troponin, fibrinogen,Coagulogram (TP, aPTT); D-dimer, Pregnancy test for non-sterile women.
Study NCT05218356 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Screening Blood tests
Description: omplete blood count, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubins and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides); coagulogram (TP, aPTT); D-dimer; C-reactive protein; HIV, HBV, HCV serology; Ferritin; troponin, fibrinogen,Coagulogram (TP, aPTT); D-dimer, Pregnancy test for non-sterile women.
Study NCT05218356 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: valuation by the principal investigator or assistant physician with a complete physical examination